A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes
Inclusion Criteria:
Exclusion Criteria:
Evansville, Kentucky, United States
Petosky, Michigan, United States
Middleburg Hights, Ohio, United States
Spartenburg, South Carolina, United States
Ciudad Autonom de Buenos Aires, Argentina
CiudadAutonoma de Buenos Aires, Argentina
Lanus Buenos Aires, Argentina
Rosario Santa Fe, Argentina
Sarandi Buenos Aires, Argentina
Chrudim III, Czechia
Olomouc-Lazce, Czechia
Ostrava - Belsky Les, Czechia
Ostrava-Vitkovice, Czechia
Valaske Klobouky, Czechia
Ernakulam District, India
Negrar - VR, Italy
S Maria Capua Vetere, Italy
Mrgowo, Poland
Nakso Nad Noteci, Poland
Aguas Buneas, Puerto Rico
Hato Rey, Puerto Rico
Jardines de Loiza, Loiza, Puerto Rico
StPetersburg, Russia
Jerez de La Frontera Cadiz, Spain
Kaohsiung Hsien, Taiwan
Bangkoknoi, Thailand
Mortimer Reading, United Kingdom